Comparison of Chemotherapy Regiments between Cisplatin Etoposide and Cisplatin-Docetaxel on 2-Year and Progression-Free Survival in Late-Stage Non-Small Cell Lung Cancer Patients

Comparison of Chemotherapy Regiments between Cisplatin Etoposide and Cisplatin-Docetaxel on 2-Year and Progression-Free Survival in Late-Stage Non-Small Cell Lung Cancer Patients

Introduction. Chemotherapy is one of therapy choices for the advanced Non-Small Cell Lung Cancer (NSCLC). The success in therapy is measured with the 1-year survival, 2-year survival and the Progression Free Survival (PFS). The success is influenced by many factors: resistant to the citostatic, dosa...

Full description

Bibliographic Details
Main Authors: Salman Paris Harahap, Noorwati Sutandyo, Cleopas Martin Rumende, Hamzah Shatri
Format: Article
Language:Indonesian
Published: Department of Internal Medicine, Faculty of Medicine Universitas Indonesia 2016-06-01
Series:Jurnal Penyakit Dalam Indonesia
Subjects:
cisplatin docetaxel
cisplatin etoposide
NSCLC
PFS
Survival
Online Access:http://jurnalpenyakitdalam.ui.ac.id/index.php/jpdi/article/view/11/11

Internet

http://jurnalpenyakitdalam.ui.ac.id/index.php/jpdi/article/view/11/11

Similar Items